✦ LIBER ✦

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

✍ Scribed by Serafín Morales; Antonio Lorenzo; Manuel Ramos; Pedro Ballesteros; Miguel Méndez; Concepción Almanza; Javier Castellanos; José Andrés Moreno-Nogueira; Joaquín Casal; José Lizón; Amparo Oltra; Adolfo Frau; Ignacio Machengs; Antonio Galán; Joaquín Belón; Cristina Llorca

Book ID: 110611302
Publisher: Springer
Year: 2004
Tongue: English
Weight: 692 KB
Volume: 53
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf02665356

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel plus epirubicin is a highly ac

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

✍ Serafín Morales; Antonio Lorenzo; Manuel Ramos; Pedro Ballesteros; Miguel Méndez 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 196 KB

Navelbine® (NVB) alternating oral and i.

Navelbine® (NVB) alternating oral and i.v. plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC): phase II study — final results

✍ D Serin; M Verrill; A Jones; T Delozier; R Coleman; B Longerey; S Lafaye de Mich 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 354 KB

Ifosfamide/liposomal daunorubicin is a w

Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma : Results of a Phase II study

✍ Jan M. Siehl; Eckhard Thiel; Alexander Schmittel; Gero Hütter; Peter M. Deckert; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

454 A phase II study of vinorebline (VRL

454 A phase II study of vinorebline (VRL) alterning oral and intravenous (IV) plus epirubicin (EPI) as first line chemotherapy of metastatic breast cancer (MBC)

✍ M. Verrill; D. Serin; A. Jones; T. Delozier; R. Coleman 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 323 KB

Multicenter phase II study of trastuzuma

Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

✍ M. Venturini; C. Bighin; S. Monfardini; F. Cappuzzo; N. Olmeo; A. Durando; F. Pu 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 218 KB

Is salvage chemotherapy for metastatic b

Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin

✍ Antonella Venturino; Danila Comandini; Carlotta Simoni; Laura Merlini; Cinzia Na 📂 Article 📅 2000 🏛 Springer US 🌐 English ⚖ 42 KB